Presentación de las primeras cinco comunidades acreditadas RIS3CAT
25 jul. 16
El 25 de julio, ACCIÓ presentó las cinco primeras comunidades acreditadas RIS3CAT. RIS3CAT es la estrategia del gobierno catalán para
El 25 de julio, ACCIÓ presentó las cinco primeras comunidades acreditadas RIS3CAT. RIS3CAT es la estrategia del gobierno catalán para
In June 2016, the Generalitat approved 5 RIS3CAT Communities corresponding to the five areas identified as priority: Technologies Applied to
TERET Nuevas Terapias en Enfermedades de Retina ABSTRACT El proyecto TERET tiene como objeto el desarrollo y mejora de nuevas
Developing new therapies for Batten disease www.batcure.eu ABSTRACT The goal of BATCure is to advance the development of new therapeutic
LEITAT Foundation, FC Barcelona Foundation and Bioiberica S.A, a biotechnology company specialised in arthritis and health, have joined forces to
LEITAT is boosting a community in the Health’s industries sector about Technologies for Health, which met in Terrassa on the
GLAM Glass-Laser Multiplexed Biosensor glam-project.eu Differential cancer diagnosis takes place daily in clinical settings for a better monitoring of patient
DENECOR Devices for NeuroControl and NeuroRehabilitation www.denecor.info ABSTRACT DeNeCor addresses the diagnosis and treatment of neurological diseases, which have an
Resorbable Ceramic Biocomposites for Orthopaedic and Maxillofacial Applications
NANO4DERM Nanocapsules containing active substances for the topical treatment of dermatological diseases ABSTRACT The research project Nano4Derm will focus on
TTPPP Application of the Transmembrane Therapeutic Protein Production Platform (TTPPP) to an innovative approach for the Treatment of Cancer or
NEQAM Development and Application of new Chemometric Strategies for Metabolomic Analysis ABSTRACT NEQAM project aims at the development, assessment and
ACINETOCLINIC Transition to Clinical Investigation Phase for Licencing of the First Vaccine Against Drug Resistent Acinetobacter Baumannii ABSTRACT Vaccines against
IDP4MM Development of drugs in new therapeutic IDP targets for the treatment of multiple myeloma ABSTRACT This project is part
TOXAB Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer ABSTRACT The main objective of the
NUEVAS DIANAS Discovery and combination of new treatments for cancer treatment based on the modulation of epigenetic targets and adenosine
Tel. (+34) 937 882 300
